PERCEPT™ PC NEUROSTIMULATOR Neurostimulator for Deep Brain Stimulation Therapy

The only complete DBS system with sensing, directionality, and visual programming giving you access to the data-driven insights you need to make informed decisions.

DOWNLOAD BROCHURE

Closeup of the Percept PC neurostimulator for deep brain stimulation.

Alert Indications, Safety, and Warnings

Overview

Percept™ PC Portfolio

Percept™ PC Neurostimulator and SenSight™ Directional Lead – the only complete DBS system designed for sensing.

WHAT IS IT

The Percept™ PC neurostimulator with BrainSense™ technology* is designed to capture a patient's brain signals, providing clinicians objective data directly from a DBS patient's brain to understand the impact of treatment decisions such as medication or stimulation changes.

Dr. Mark Richardson discusses how BrainSense technology works with deep brain stimulation therapy.
More information (see more) Less information (see less)

HOW IT WORKS

BrainSense™ technology captures brain signals (local field potentials, or LFPs) using the implanted DBS lead. These signals can be recorded simultaneously while delivering therapeutic stimulation, inside and outside the clinic.* Clinicians can also correlate these brain signals with stimulation and patient-captured events such as medication, symptoms, or side effects.

Watch the animation to learn more about how BrainSense™ technology works.
More information (see more) Less information (see less)

Percept™ PC
Neurostimulator

The state-of-the-art Percept™ PC device is also
designed to facilitate expanded capabilities in the
future via software upgrades — so you’re prepared
for what’s next in DBS.

ENHANCED BRAINSENSE™ SURVEY

See electrode-level comparisons — between
segmented levels, among segments within each
level, and in each direction between the two levels.

ENGINEERED FOR
PATIENT COMFORT

Ergonomically designed, the Percept™ PC
device offers enhanced comfort for patients.

* In overall device volume.
^†Refers to case thickness.

Percept™ PC NEUROSTIMULATORWITH BRAINSENSE™ TECHNOLOGY

The only 3T and 1.5T MR Conditional^‡ DBS
system with a directional, sensing lead

DESIGNED TO LAST LONGER
— AND KEEP YOU INFORMED

The Percept™ PC device offers improved longevity^††and features smart battery technology**

SIMPLE.
PERSONAL.
SMART.

The DBS Patient Programmer is enhanced so patients can more easily and conveniently engage with their therapy.

^‡Medtronic DBS systems are MR Conditional and safe in the MR environment as long as certain conditions are met. If the conditions are not met, a significant risk is tissue lesions from component heating, especially at the lead electrodes, resulting in serious and permanent injury including coma, paralysis, or death. Refer to the MRI Guidelines for Medtronic Deep Brain Stimulation Systems for a complete list of conditions: http://professional.medtronic.com/mri
** Based on current actual battery level and therapy settings from last seven days.
^††For median energy use in DBS for patients with Parkinson’s disease, with moderate (up to two months per year) BrainSense™ technology usage.

Unprecedented Insights Inside or Outside of the Clinic

The Percept™ PC device features BrainSense™ technology*, designed to capture brain signals (local field potentials, or LFPs) using the implanted DBS lead. These signals can be recorded simultaneously while delivering therapeutic stimulation, inside and outside the clinic.

You can correlate these brain signals with stimulation and events capturing medication, symptoms, or side effects — to deliver personalized, data-driven treatment and adjust as patient needs evolve.*

A sample graph from a Brainsense survey on an iPad

Percept™ PC Neurostimulator and Sensight™ Directional Lead The only complete DBS System designed for sensing

LFPs are 1 million times smaller than DBS stimulation pulses¹
Improved insulation for enhanced detection of LFPs with the Percept™ PC neurostimulator with BrainSense™ technology*
The SenSight™ directional lead was developed with proprietary materials, components, and processes used to meet rigorous specifications designed for sensing.

Unlock Your Programming Potential

OptiStim™ and ShapeLock™ Controls along with multiple-rate features are enabled by the 16 independent current sources in the Percept™ PC device, giving you access to our widest range of programming options ever.

OPTISTIM™ CONTROL

OptiStim™ control allows you to assign unique amplitude values to each electrode. Add or subtract segments from the configuration without dropping amplitude of all electrodes to zero (in unipolar mode).

SHAPELOCK™ CONTROL

After achieving desired stimulation shape with OptiStim™ control, use ShapeLock™ control to seamlessly increase or decrease the shape created — an intuitive interface for advanced programming needs.

MULTIPLE RATES

Select a pair of rates and assign any electrode across the two leads to one of the two rates.

Assign different rates by electrode — to electrodes in different hemispheres or to different electrodes on the same lead.

PRODUCT SPECIFICATIONS

Compatible with:

SenSight™ lead models B33005 and B33015
Lead model 3387
Lead model 3389
Lead model 3391
SenSight™ Extension model B34000
Extension model 37086
Clinician programmer CT900D (tablet) with clinican programmer software application A610, and communicator model 8880T2
DBS patient programmer model TH91D with patient programmer software application A620

Model Specifications

Model	B35200
Battery	Primary Cell
Weight	61g
Height	68mm
Length	51mm
Channels	2

PRODUCT SUPPORT

Clinician Services
800-328-0810

MANUALS AND MRI GUIDELINES

Search by product name or model number.

VISIT LIBRARY

The sensing feature of the Percept™ PC device is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status. Signal may not be present or measurable in all patients. Clinical benefits of brain sensing have not been established.

BCC Research Report HLC078D: Medical Magnetic Resonance Imaging (MRI) Technologies and Global Markets (July 2018).